Blocking the expression of PERK can inhibit the downstream metabolic signaling in tumor-infiltrating macrophages, resulting in more effector T cells to fight the cancer cells and consequently enhancing the efficacy of PD-1 inhibitors (45). The gene discussed is PDCD1; the disease is cancer.